Specificity of vascular endothelial growth factor treatment for radiation necrosis

Abstract Recently, radiation induced necrosis in the brain has been treated using bevacizumab, an anti-VEGF antibody. We validated the VEGF specificity by comparing the therapeutic efficacy of anti-VEGF with non-specific isotype control antibody. Additionally, we found that VEGF over-expression and...

Full description

Saved in:

Bibliographic Details
Published in:	Radiotherapy and oncology Vol. 117; no. 2; pp. 382 - 385
Main Authors:	Perez-Torres, Carlos J, Yuan, Liya, Schmidt, Robert E, Rich, Keith M, Drzymala, Robert E, Hallahan, Dennis E, Ackerman, Joseph J.H, Garbow, Joel R
Format:	Journal Article
Language:	English
Published:	Ireland Elsevier Ireland Ltd 01-11-2015
Subjects:	Animals Brain - pathology Brain - radiation effects Disease Models, Animal Female Hematology, Oncology and Palliative Medicine Magnetic Resonance Imaging Mice Mice, Inbred BALB C Necrosis - drug therapy Radiation Injuries, Experimental - therapy Radiation necrosis Sensitivity and Specificity Vascular endothelial growth factor Vascular Endothelial Growth Factor A - therapeutic use Magnetic resonance imaging Vascular endothelial growth factor Radiation necrosis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Recently, radiation induced necrosis in the brain has been treated using bevacizumab, an anti-VEGF antibody. We validated the VEGF specificity by comparing the therapeutic efficacy of anti-VEGF with non-specific isotype control antibody. Additionally, we found that VEGF over-expression and RN developed simultaneously, which precludes preventative anti-VEGF treatment.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0167-8140 1879-0887
DOI:	10.1016/j.radonc.2015.09.004